Nirsevimab + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Lower Respiratory Tract Infection
Conditions
Lower Respiratory Tract Infection
Trial Timeline
Nov 24, 2021 → Nov 24, 2025
NCT ID
NCT05110261About Nirsevimab + Placebo
Nirsevimab + Placebo is a phase 3 stage product being developed by AstraZeneca for Lower Respiratory Tract Infection. The current trial status is active. This product is registered under clinical trial identifier NCT05110261. Target conditions include Lower Respiratory Tract Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05110261 | Phase 3 | Active |
Competing Products
20 competing products in Lower Respiratory Tract Infection